News

Qualigen Therapeutics, Inc. announces it has entered into an agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd, of Suzhou, China to develop, manufacture and sell new generations of…
Read More...

Johnson & Johnson announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen…
Read More...

Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals Inc. announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference…
Read More...

Pfizer Inc. and Sangamo Therapeutics, Inc. a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene…
Read More...

OliX Pharmaceuticals announced a collaboration with Théa Open Innovation, a sister company of Laboratoires Théa S.A.S ("Théa"), the leading independent pharmaceutical company in Europe …
Read More...

Citius Pharmaceuticals, Inc. a specialty pharmaceutical company developing and commercializing critical care drug products, announced that it has signed an exclusive agreement with…
Read More...

Vir Biotechnology, Inc. and GlaxoSmithKline plc announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study…
Read More...

Oragenics, Inc. announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (“FDA”) that it is in broad agreement with the Company’s…
Read More...

Pfizer Inc. and BioNTech SE announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine…
Read More...

Aro Biotherapeutics, a biotechnology company focused on developing a new generation of medicines based on its proprietary CENTYRIN technology, announced that Ionis Pharmaceuticals,…
Read More...

Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, announced a research collaboration with Biogen Inc. to develop…
Read More...

ImmunoGen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or…
Read More...

GlycoMimetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sickle…
Read More...

Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the Company has initiated a Phase I/II…
Read More...

SpringWorks Therapeutics, Inc. announced that the company has entered into a clinical trial collaboration agreement with Pfizer Inc. (NYSE: PFE) to evaluate SpringWorks Therapeutics’…
Read More...

Nimble Therapeutics Inc. announced the company has entered into a strategic collaboration with Incyte to discover first-in-class peptide therapies across various disease areas. “This…
Read More...

Bristol Myers Squibb and MyoKardia, Inc. announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash.…
Read More...

NVIDIA announced a partnership with global healthcare company GSK and its AI group, which is applying computation to the drug and vaccine discovery process. GSK has recently…
Read More...

BONE THERAPEUTICS, the cell therapy company addressing unmet medical needs in orthopedics and other diseases, Link Health Pharma Co., Ltd and Shenzhen Pregene Biopharma Company, Ltd…
Read More...

Bristol Myers Squibb announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the…
Read More...